Effects of Desmodium caudatum on Gastrointestinal Hormones and Intestinal Flora in Rats with Gastritis
March 1st, 2024
The present protocol describes the method for analyzing intestinal flora using Illumina-based 16S rRNA gene sequencing and provides a framework for evaluating the effectiveness of herbal decoctions.
As an indispensable component of the treasure trove of traditional Chinese medicine, folk medical materials hold great significance for clinical practice and modernization of national medicine. This article aims to study the effects of D.caudatum in treating gastritis based on gastrointestinal hormones and intestinal flora, providing a basis for its rational clinical application. Numerous studies have reported that the occurrence and development of chronic gastritis are linked to the secretion of gastrointestinal hormones, such as gastrin.
It can be utilized as an indicator to evaluate the development level of chronic gastritis. Furthermore, lipid peroxidation products triggered by reactive oxides can activate inflammatory cells, leading to chronic gastritis. In 16S rRNA high-throughput gene sequencing, low resolution may make it challenging to distinguish strains and genera with highly similar sequences, leading to difficulties in classification at higher taxonomic levels, such as genus, family, and phylum.
For the ELISA kit method, sample pretreatment steps like dilution and washing are usually required, introducing potential errors and variabilities. To prepare a 5%sodium salicylate solution, weigh 2.5 grams of powder on an electronic scale. Dissolve the powder in a small amount of distilled water.
And dilute it to a total volume of 50 milliliters. For the preparation of a decoction of Desmodium caudatum weigh 128 grams of D.Caudatum. And place it into a round bottom flask containing 1 liter of distilled water.
Concentrate the mixture to a final volume of 100 milliliters. Based on treatment, divide the rats into different groups. After sacrificing the rat by cervical dislocation, in the serum sample, measure the contents of gastrin and malondialdehyde using ELISA on a microplate reader.
In the pathological study of the stomach wall compared to rats from the control group, model group exhibited mild gastric wall atrophy and mild inflammation. In contrast, rats treated with D.caudatum decoction presented no inflammation, metaplasia, or atrophy, indicating the decoction's therapeutic effect. Serum gastrointestinal hormone assays revealed that rats in model groups had higher malondialdehyde levels than control group rats, which significantly decreased in post-treatment.
Gastrin levels were lower in model group rats compared to the control group, but increased significantly in the decoction-treated group, suggesting the decoction's efficacy in modulating gastrointestinal hormones.
Overview
This article investigates the effects of D.caudatum on gastritis through the lens of gastrointestinal hormones and intestinal flora. It employs 16S rRNA gene sequencing to analyze intestinal flora and assess the impact of herbal decoctions.
Key Study Components
Area of Science
- Neuroscience
- Gastroenterology
- Traditional Chinese Medicine
Background
- Chronic gastritis is associated with gastrointestinal hormone secretion.
- Gastrin serves as an indicator for evaluating chronic gastritis.
- Lipid peroxidation products can activate inflammatory cells, contributing to gastritis.
- 16S rRNA sequencing may face challenges in distinguishing closely related strains.
Purpose of Study
- To evaluate the clinical application of D.caudatum in treating gastritis.
- To understand the relationship between gastrointestinal hormones and intestinal flora.
- To provide a framework for analyzing herbal decoctions.
Methods Used
- 16S rRNA gene sequencing for intestinal flora analysis.
- Evaluation of gastrointestinal hormone levels.
- Assessment of the effects of D.caudatum on gastritis.
- Analysis of lipid peroxidation products in relation to inflammation.
Main Results
- D.caudatum shows potential in influencing gastrointestinal hormones.
- Intestinal flora analysis reveals significant findings related to gastritis.
- Challenges in strain classification were noted during sequencing.
- The study supports the rational use of herbal decoctions in clinical settings.
Conclusions
- D.caudatum may be beneficial in treating gastritis.
- Understanding gastrointestinal hormones is crucial for gastritis management.
- Further research is needed to refine classification methods in 16S rRNA sequencing.
Frequently Asked Questions
Executive Industry Relevance
Quantitative assessment of gastrointestinal hormones and intestinal flora in preclinical gastritis models enables mechanistic de-risking and target validation for gut-related therapeutic strategies. The integration of ELISA-based hormone quantification and 16S rRNA gene sequencing provides predictive confidence for early discovery teams evaluating botanical interventions. These approaches support portfolio decisions by clarifying biological impact and translational potential in gastrointestinal disease models.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of therapeutic hypotheses linking botanical extracts to hormone modulation and microbiome shifts.
- Supports biological de-risking by quantifying gastrin and malondialdehyde as mechanistic biomarkers.
- Facilitates functional target validation through comparative analysis across control, disease, and treatment groups.
Screening & Assay Development
- Establishes validated ELISA and 16S rRNA workflows for reproducible measurement of hormone and microbiome endpoints.
- Provides quantitative outputs for assay standardization and cross-study comparability.
- Enables screening of additional compounds or extracts for effects on gut hormone and flora profiles.
Translational & Preclinical Research
- Aligns preclinical model outputs with disease-relevant biomarkers for translational continuity.
- Supports risk-adjusted advancement by linking molecular and microbial endpoints to therapeutic effect.
- Offers predictive de-risking for botanical candidates targeting gastrointestinal disorders.
Pipeline & Workflow Integration
This workflow positions ELISA-based hormone quantification and 16S rRNA microbiome profiling at the interface of early discovery and preclinical validation for gastrointestinal targets.
- Discovery Biology: Supports hypothesis testing on the interplay between botanical extracts, hormone regulation, and microbiome composition.
- Screening: Delivers reproducible, quantitative readouts for compound evaluation and assay development.
- Analytics: Provides statistical outputs for comparing treatment effects on gastrin, malondialdehyde, and microbial diversity.
- Translational Research: Bridges preclinical findings to disease-relevant biomarkers for downstream validation.
- Enterprise Reuse: Establishes a reusable platform for evaluating gut-targeted interventions in rodent models.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in gut-targeted discovery programs.
- Operational Value: Standardizes hormone and microbiome assays for reproducibility and scalability.
- Strategic Value: Informs go/no-go decisions and enhances capital efficiency by clarifying biological impact early.
- Portfolio Impact: Enables risk-adjusted prioritization of botanical and microbiome-modulating candidates.
Implementation Considerations
- Requires expertise in ELISA, 16S rRNA sequencing, and rodent model handling.
- Demands access to microplate readers, sequencing platforms, and bioinformatics tools.
- Necessitates cross-team standardization of sample preparation and data analysis protocols.
- May require adaptation for different botanical extracts or disease models.
- Sequencing resolution and ELISA variability must be managed for robust outputs.
